Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors

Hormone and Metabolic Research

Volumn 42, Issue 8, 2010, Pages 599-606

  Mussig K ^a   Oksuz M O ^a   Dudziak, K ^a   Ueberberg, B ^b   Wehrmann, M ^a   Horger, M ^a   Schulz, S ^c   Haring H U ^a   Pfannenberg, C ^a   Bares, R ^a   Gallwitz, B ^a   Petersenn, S ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

NET; neuroendocrine tumors; sst; 111In DTPAOC; 68Ga DOTA Tyr octreotide

Indexed keywords

IOPROMIDE; OCTREOTIDE [3 TYROSINE 1 DEXTRO PHENYLALANINE] PENTETIC ACID GA 68; PENTETIC ACID OCTREOTIDE IN 111; POLYCLONAL ANTIBODY; SOMATOSTATIN RECEPTOR 2; TRACER; UNCLASSIFIED DRUG; EDOTREOTIDE; OCTREOTIDE; PENTETIC ACID; SDZ 215-811; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGING; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SCINTIGRAPHY; SCORING SYSTEM; ANALOGS AND DERIVATIVES; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PENTETIC ACID; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77954228507     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1253354     Document Type: Article

References (20)

1. Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y, Arnold R. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002 50 52-60
2. Slooter GD, Mearadji A, Breeman WA, Marquet RL, de Jong M, Krenning EP, van Eijck CH. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg 2001 88 31-40
3. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, Weber HC, Stewart CA, Jensen RT. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996 125 26-34
4. Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, McIlrath EM. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM 1998 91 295-301
5. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, Schilling T, Haufe S, Herrmann T, Haberkorn U. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007 34 1617-1626
6. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006 33 460-466
7. Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 1999 40 762-767
8. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Mäcke HR, Chinol M, de Braud F. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001 28 426-434
9. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumors: a clinical phase II study. Ann Oncol 2001 12 941-945
10. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008 9 61-72
11. Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Saeger W, Schmid KW, Mann K, Petersenn S. Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumors. Clin Endocrinol (Oxf) 2008 68 850-857
12. Fischer T, Doll C, Jacobs S, Kolodziej A, Stumm R, Schulz S. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 2008 93 4519-4524
13. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, Jahn M, Jennewein M, RÖsch F. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007 48 1741-1748
14. Dimitroulopoulos D, Xynopoulos D, Tsamakidis K, Paraskevas E, Zisimopoulos A, Andriotis E, Fotopoulou E, Kontis M, Paraskevas I. Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis. World J Gastroenterol 2004 10 3628-3633
15. Cimitan M, Buonadonna A, Cannizzaro R, Canzonieri V, Borsatti E, Ruffo R, De Apollonia L. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 2003 14 1135-1141
16. Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007 20 1172-1182
17. Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 2008 26 963-970
18. Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, Perren A. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in (68)Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009 36 48-52
19. Ueberberg B, Tourne H, Redman A, Walz MK, Schmid KW, Mann K, Petersenn S. Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Horm Metab Res 2005 37 722-728
20. Tulipano G, Schulz S. Novel insights in somatostatin receptor physiology. Eur J Endocrinol 2007 156 S3-S11